Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant,Clinical Microbiology Reviews

当前位置： X-MOL 学术 › Clin. Microbiol. Rev. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant
Clinical Microbiology Reviews ( IF 19.0 ) Pub Date : 2022-06-06 , DOI: 10.1128/cmr.00014-22
Hao Zhou _{1,

2} , Michelle Møhlenberg _{3,

4} , Jigarji C Thakor ₅ , Hardeep Singh Tuli ₆ , Pengfei Wang ₇ , Yehuda G Assaraf ₈ , Kuldeep Dhama ₅ , Shibo Jiang ₉

Affiliation

Department of Microbiology, NYU Grossman School of Medicine, New York, New York, USA.
College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Department of Biomedicine, Aarhus University, Aarhus, Denmark.
Center for Cancer Biology, Department of Oncology, VIB-KU Leuven, Leuven, Belgium.
Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh, India.
Department of Biotechnology, Maharishi Markandeshwar (Deemed University), Mullana, Ambala, Haryana, India.
State Key Laboratory of Genetic Engineering, Shanghai Institute of Infectious Disease and Biosecurity, School of Life Sciences, Fudan University, Shanghai, China.
The Fred Wyszkowski Cancer Research Laboratory, Faculty of Biology, Technion Israel Institute of Technology, Haifa, Israel.
Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Fudan University, Shanghai, China.